Administration of Brincidofovir and Convalescent Plasma in a Patient With Ebola Virus Disease

被引：69
作者：
Florescu, Diana F. [1 ,2 ]
Kalil, Andre C. [1 ]
Hewlett, Angela L. [1 ]
Schuh, Amy J. [3 ,4 ]
Stroher, Ute [3 ,4 ]
Uyeki, Timothy M. [5 ]
Smith, Philip W. [1 ]
机构：
[1] Univ Nebraska, Med Ctr, Div Infect Dis, Omaha, NE 68182 USA
[2] Univ Nebraska, Med Ctr, Transplant Surg Program, Omaha, NE 68182 USA
[3] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens, Atlanta, GA USA
[4] Ctr Dis Control & Prevent, Pathol Natl Ctr Emerging & Zoonot, Atlanta, GA USA
[5] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA
来源：
CLINICAL INFECTIOUS DISEASES | 2015年 / 61卷 / 06期
关键词：
Ebola; investigational therapies; trials; HUMORAL IMMUNE-RESPONSE; HEMORRHAGIC-FEVER; CMX001; SUDAN; INFECTIONS; OUTBREAK; GULU;
D O I：
10.1093/cid/civ395
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
From 2014 to May 2015, >26 000 Ebola virus disease (EVD) cases were reported from West Africa. We present a patient with EVD who received brincidofovir and convalescent plasma. The relative contributions of supportive care, investigational therapies, and patient's immune-response on survival could not be determined. Randomized trials are needed.
引用
收藏
页码：969 / 973
页数：5
相关论文
共 21 条
  • [1] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells
    Andrei, G
    Snoeck, R
    Schols, D
    De Clercq, E
    [J]. ONCOLOGY RESEARCH, 2001, 12 (9-10) : 397 - 408
  • [2] [Anonymous], 2016, Ebola Situation Report
  • [3] Identification of Continuous Human B-Cell Epitopes in the VP35, VP40, Nucleoprotein and Glycoprotein of Ebola Virus
    Becquart, Pierre
    Mahlakoiv, Tanel
    Nkoghe, Dieudonne
    Leroy, Eric M.
    [J]. PLOS ONE, 2014, 9 (06):
  • [4] Ebola Virus Disease in West Africa - Clinical Manifestations and Management
    Chertow, Daniel S.
    Kleine, Christian
    Edwards, Jeffrey K.
    Scaini, Roberto
    Giuliani, Ruggero
    Sprecher, Armand
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (22) : 2054 - 2057
  • [5] CASE OF EBOLA VIRUS-INFECTION
    EMOND, RTD
    EVANS, B
    BOWEN, ETW
    LLOYD, G
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1977, 2 (6086): : 541 - 544
  • [6] Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses
    Florescu, Diana F.
    Keck, Megan A.
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2014, 12 (10) : 1171 - 1178
  • [7] Studying "Secret Serums" - Toward Safe, Effective Ebola Treatments
    Goodman, Jesse L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (12) : 1086 - 1089
  • [8] Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections
    Jahrling, PB
    Geisbert, TW
    Geisbert, JB
    Swearengen, JR
    Bray, M
    Jaax, NK
    Huggins, JW
    LeDuc, JW
    Peters, CJ
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 179 : S224 - S234
  • [9] Ebola hemorrhagic fever: Evaluation of passive immunotherapy in nonhuman primates
    Jahrling, Peter B.
    Geisbert, Joan B.
    Swearengen, James R.
    Larsen, Thomas
    Geisbert, Thomas W.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2007, 196 : S400 - S403
  • [10] Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections
    Kudoyarova-Zubavichene, NM
    Sergeyev, NN
    Chepurnov, AA
    Netesov, SV
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 179 : S218 - S223
123